Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.37 |
| ▸ | JAK2 | O60674 | 6/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2088075 | 1.00 | GPR119 (0.37) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL1498950 | 0.91 | JAK2 (0.37) | JAK2JAK1TYRO3AXLMERTK | |
| SCHEMBL1498852 | 0.90 | TYRO3 (0.44) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL1498925 | 0.90 | TYRO3 (0.44) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL1499317 | 0.90 | JAK2 (0.43) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL30100141 | 0.90 | TYRO3 (0.44) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL1498942 | 0.87 | TYRO3 (0.42) | GPR119JAK2JAK1TYRO3AXL | |
| SCHEMBL859507 | 0.87 | JAK2 (0.41) | JAK2JAK1TYRO3AXLMERTK | |
| SCHEMBL19928588 | 0.87 | JAK1 (0.41) | JAK2JAK1TYRO3AXLMERTK | |
| SCHEMBL1498952 | 0.87 | TYRO3 (0.37) | GPR119JAK2JAK1TYRO3AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249145-B2 | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-02-02 | — | — | US | disclosed |
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059951-A1 | HETEROCYCLIC DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | GPR119 3664/4885JAK2 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.